Tetrodotoxin

- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction - ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025. “The Company continues to execute at a high level, including recruitment of 100 patients in our ongoing Halneuron® Phase 2b trial and the addition of a, synergistic and complementary pipeline asset, SP16, a novel, first-in-class development candidate for cancer related pain,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “We are excited for our journey ahead and look forward to delivering on our target milestones, including an update on our interim analysis on our Halneuron® CINP Phase 2b trial in Q4 2025, with final data for the full 200 patient data set expected in the second half of 2026, as well as garnering FDA feedback for our proposed SP16 Phase 1b study that is fully funded by the National Cancer Institute.” Third Quarter 2025 Financial Results Research and development expenses for the third quarter of 2025 were $14.5 million, compared to $0.5 million for the third quarter of 2024. The $14.0 million increase quarter over quarter was primarily related to acquired in-process research and development expenses of $12.0 million associated with the licensing agreement of SP16, the impact of the business combination with Pharmagesic (Holdings) Inc., including increases in expenses for clinical trials of $1.9 million related to the Halneuron® CINP Phase 2b study, as well as drug development and manufacturing costs of $0.3 million and salaries and related personnel costs of $0.1 million, offset by a decrease in research and preclinical costs of $0.3 million. General and administrative expenses for the third quarter of 2025 were $1.3 million, compared to $1.8 million for the third quarter of 2024. The $0.5 million decrease quarter over quarter was primarily due to a decrease in legal and accounting fees of $0.5 million and a decrease in expenses associated with being a public company of $0.2 million, offset by an increase in salaries and related personnel costs of $0.2 million. Net loss attributable to common stockholders for the third quarter of 2025 was $15.7 million, or $8.20 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $2.3 million, or $2.05 basic and diluted net loss per share, for the third quarter of 2024. Cash on hand of $10.1 million provides operational runway through the first quarter of 2026. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the Food and Drug Administration (“FDA”) for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). SP16 IV is a low-density lipoprotein receptor related protein-1 (LRP1) agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial will commence following consultation with FDA and is fully funded by the National Cancer Institute. For more information, please visit www.dwtx.com. Forward-Looking Statements: Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Investor Relations: CORE IR(516) 222-2560IR@dwtx.com -Financial Tables Follow- DOGWOOD THERAPEUTICSSelected Financial Data (unaudited) Condensed Statements ofOperations Data Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2025 2024 2025 2024 Revenue $— $— $— $— Operating expenses: Research and development 14,521,342 535,162 19,528,283 1,214,964 General and administrative 1,287,783 1,766,010 4,633,883 3,470,133 Total operating expenses 15,809,125 2,301,172 24,162,166 4,685,097 Loss from operations (15,809,125) (2,301,172) (24,162,166) (4,685,097)Other income (expense): Loss on debt conversion with related party — — (6,134,120) — Interest income, net 80,582 20,488 44,871 63,245 Exchange loss, net (17,509) — (36,251) — Total other income (expense) 63,073 20,488 (6,125,500) 63,245 Loss before income taxes (15,746,052) (2,280,684) (30,287,666) (4,621,852)Deferred income tax benefit (expense) 1,436 — (189,255) — Net Loss (15,744,616) (2,280,684) (30,476,921) (4,621,852)Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock — — (1,256,662) — Net loss attributable to common stockholders $(15,744,616) $(2,280,684) $(31,733,583) $(4,621,852)Net loss per common share — basic and diluted $(8.20) $(2.05) $(18.02) $(4.95)Weighted average number of shares outstanding — basic and diluted 1,919,433 1,110,317 1,761,237 932,872 Condensed Consolidated Balance Sheet DataSeptember 30, December 31, 2025 2024 Cash$10,126,710 $14,847,949 Total assets 91,992,613 94,308,246 Total liabilities 14,607,504 30,027,223 Total stockholders’ equity (deficit) 7,258,152 (10,124,339) Source: Dogwood Therapeutics, Inc.

编者按 近年来，市委组织部、市委人才工作局紧紧围绕全市中心大局，牢固树立“人才是第一资源”的理念，坚持开展选派省内高校专技人才挂职工作。三年来，在省委组织部、省教育厅的有力支持下，从省内17所高校选派370余名专技人才赴我市基层企事业单位挂职锻炼。广大挂职专业技术人才充分立足单位实际，发挥自身专业特长，积极帮助挂职单位开展技术攻关、成果转化、人才培养等工作，为我市经济社会发展注入了新的智慧与活力。现将部分高校挂职专业技术人才服务地方发展工作风采予以刊发，以期激励更多挂职人才建功立业。 深耕科研助力企业跨越提升 ——安徽医科大学教授  张 智 一 基本情况 张智，男，汉族，1979年7月出生，安徽滁州人，安徽医科大学教授、学术副校长。2024年4月至2025年4月，挂职安徽华沐生物科技有限公司科技副总，主要负责公司新项目立项及运营工作。张智教授长期致力于慢性疼痛机制研究，在抑郁、焦虑、慢性疼痛等神经机制解析方面取得多项突破性成果，以最后通讯作者身份在Science等国际顶级期刊发表多篇论文。曾两次作为首席科学家牵头科技部重点科技创新计划，具备卓越的科研组织管理与团队领导能力。 二 主要工作 01 牵头国家级重点项目，构建产学研协同创新体系 积极推动华沐生物成功入选国家自然科学基金委员会—2024年度长三角基础研究联合基金项目。该项目由安徽医科大学作为牵头单位，负责镇痛机制研究与替曲朵辛制剂的功能评价；中国科学院合肥物质科学研究院参与承担代謝流分析与发酵精准调控任务；华沐生物负责规模化制备、中试生产线建设及产品应用推广。合作单位覆盖研发、生产与应用全链条，在基础研究、技术突破与产品开发方面各具优势，资源互补，形成强大合力，对行业技术进步与产业升级具有重要推动意义。 张智教授与华沐生物负责人签约。 02 加速新药临床转化，突破镇痛领域研发瓶颈 2025年1月，FDA批准了数十年来首个以钠离子通道为靶点的非阿片类镇痛药物，而华沐生物在研药物替曲朵辛正属于高效钠离子通道阻滞剂之一。2025年4月，公司核心化合物专利获国家知识产权局授权。张智教授迅速响应，立即组织药学、临床研究、CRO等专业团队，全力推进替曲朵辛进入临床试验阶段，为企业核心产品的临床转化奠定坚实基础。 张智教授指导华沐生物项目团队。 03 打造海洋毒素开发平台，拓展神经类药物新路径 自然界中存在大量高活性天然分子，如石房蛤毒素、芋螺毒素、海蛇毒素、海葵毒素等，具有高效镇痛、局部麻醉、解痉等作用，或可特异性作用于多种神经受体与离子通道，极具新药开发潜力。然而，这类分子普遍因活性过高，直接成药难度大。张智教授指导企业建立海洋毒素开发平台，运用前药技术成功拓宽替曲朵辛的治疗窗口，为一系列海洋来源高活性分子的新药研发开辟可行路径。 张智教授在实验室检测样本。 三 工作展望 基于一年挂职的实践与思考，张智教授下一步将重点围绕以下方面开展工作：一是推动资源与产业对接。深入梳理六安资源优势，构建校企常态化对接机制，助力资源向产业优势转化。二是搭建产学研合作平台。积极推动共建研发平台与技术转移中心，引导师生团队深入产业一线。三是聚焦产业攻关服务地方。围绕生物医药等领域关键需求，联合企业开展技术研发与成果转化，推动创新链与产业链深度融合，切实服务革命老区振兴发展。 往期精选                                                                             中共中央关于制定国民经济和社会发展第十五个五年规划的建议【产教融合赋发展 校地合作谋新章】高校专业技术人才服务六安发展工作案例展播（一）【产教融合赋发展 校地合作谋新章】高校专业技术人才服务六安发展工作案例展播（二） 来源：市委人才工作局 觉得好看，请点这里↓↓↓